CXCR2 and neoplasm: In addition, we demonstrated that co-expressing a chemokine receptor (CXCR2) with the CAR construct significantly improved overall canine CAR T cell anti-tumor activity, consistent with our previous work demonstrating enhanced human CAR T cell activity against rhabdomyosarcoma [44] .